
|Videos|February 9, 2015
The Mechanism of Action and Toxicity Profile of Duvelisib (IPI-145)
Author(s)Ian W. Flinn, MD, PhD
Ian W. Flinn, MD, PhD, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.
Advertisement
Clinical Pearls
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.
- Duvelisib inhibits both delta and gamma isoform.
- The hope is that the molecule targets both the tumor cell as well as the microenvironment.
- The toxicity profile of duvelisib is still being studied.
- To date, the molecule appears to have a similar toxicity profile of other PI3K inhibitors.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
New OrigAMI-1 Data Signal Shift Beyond First-Gen EGFR Inhibitors in Metastatic CRC
2
EMA Validates T-DXd for First-Line HER2+ Metastatic Breast Cancer
3
Epcoritamab Monotherapy Yields Positive Results in Phase 3 R/R DLBCL Trial
4
Breakthroughs in Oncology: Validating Real Gains in Cancer Survival
5













































